Drugs Containing Excipient (Inactive Ingredient) POLYSORBATE 40

Branded drugs containing POLYSORBATE 40 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	TAZORAC	tazarotene	0023-8335	POLYSORBATE 40
Parke-Davis Div of Pfizer Inc	DILANTIN-125	phenytoin	0071-2214	POLYSORBATE 40
Almirall LLC	TAZORAC	tazarotene	16110-833	POLYSORBATE 40

Generic drugs containing POLYSORBATE 40 excipient

Company	Ingredient	NDC	Excipient
Allergan Inc	tazarotene	0023-8335	POLYSORBATE 40
Parke-Davis Div of Pfizer Inc	phenytoin	0071-2214	POLYSORBATE 40
E Fougera & Co a division of Fougera Pharmaceuticals Inc	hydrocortisone	0168-0288	POLYSORBATE 40

Last updated: August 22, 2026

Polysorbate 40 is a mature, low-cost pharmaceutical excipient with limited standalone patent protection and a market shaped by formulation demand, GMP quality, raw-material economics, and supplier qualification. Its commercial value is higher in regulated pharmaceutical grades than in industrial or food grades. Demand should track steady growth in oral, topical, and selected parenteral formulations, but polysorbate 20 and polysorbate 80 remain stronger competitors in biologics and injectable drug products.

Polysorbate 40 Pharmaceutical Excipient Market Dynamics and Financial Trajectory

What is polysorbate 40 and how is it used in pharmaceuticals?

Polysorbate 40 is polyoxyethylene (20) sorbitan monopalmitate. It is also identified by CAS No. 9005-66-7 and is commonly associated with the trade name Tween 40.

Its principal functions are:

• Solubilizer for poorly water-soluble active pharmaceutical ingredients
• Emulsifier in liquid and semisolid formulations
• Wetting agent
• Stabilizer for dispersed systems
• Surfactant in oral, topical, and selected injectable products

The molecule contains a sorbitan esterified with palmitic acid and approximately 20 oxyethylene units. The C16 palmitate chain distinguishes it from polysorbate 20, which is based primarily on laurate, and polysorbate 80, which is based primarily on oleate.

Attribute	Polysorbate 40
Chemical name	Polyoxyethylene (20) sorbitan monopalmitate
CAS number	9005-66-7
Common name	Tween 40
Functional class	Nonionic surfactant, emulsifier, solubilizer
Primary lipophilic chain	Palmitate, C16
Typical formulation role	Solubilization, wetting, emulsion stabilization
Pharmaceutical status	Compendial excipient where applicable
Orange Book status	Not independently listed as an active ingredient
Patent profile	Primarily process, grade, formulation, and application claims rather than basic composition claims

The U.S. Food and Drug Administration’s Inactive Ingredient Database records excipient use by dosage form and route, but it does not function as a standalone approval certificate for a particular supplier or grade. Pharmaceutical developers must still qualify identity, purity, residual solvents, microbial quality, peroxide level, and batch consistency (FDA, 2024).

What pharmaceutical products use polysorbate 40?

Polysorbate 40 is used mainly in formulations where surfactant performance and compatibility with the active ingredient are more important than high-volume biologic platform adoption.

Oral formulations

Potential oral uses include:

• Solutions and suspensions
• Soft gelatin and hard capsule formulations
• Taste-masked liquids
• Poorly soluble drug formulations
• Nutraceutical and pharmaceutical emulsions

The excipient can improve wetting and dispersion, but its use depends on dose, gastrointestinal tolerance, flavor profile, and compatibility with preservatives and container systems.

Topical and dermatological formulations

Polysorbate 40 can support:

• Creams and lotions
• Emulsions
• Gels
• Ophthalmic-adjacent formulations where permitted by the relevant regulatory framework
• Dermatological products containing poorly water-soluble ingredients

Topical demand is commercially important because it allows suppliers to sell pharmaceutical, cosmetic, and personal-care grades. The price and qualification requirements differ sharply between these categories.

Parenteral and biologic formulations

Polysorbate 40 has a more limited position in parenteral and biologic formulations than polysorbate 20 and polysorbate 80. Developers usually select a surfactant after evaluating:

• Protein aggregation
• Subvisible particles
• Oxidation
• Hydrolysis
• Container closure interaction
• Compatibility with agitation and freeze-thaw cycles
• Extractables and leachables
• Immunogenicity risk

Polysorbate 40 may be considered where its palmitate chain offers an acceptable balance of hydrophobicity and stability. It does not have the same established platform status in monoclonal antibodies as polysorbate 20 or 80.

How does polysorbate 40 compare with polysorbate 20 and polysorbate 80?

Polysorbate 40 competes primarily on formulation performance, supply reliability, and quality documentation. It does not compete only on unit price.

Attribute	Polysorbate 20	Polysorbate 40	Polysorbate 80
Principal fatty acid	Laurate, C12	Palmitate, C16	Oleate, C18:1
Common biologic use	High	Limited to moderate	High
Oxidation sensitivity	Material-dependent	Generally lower than oleate-rich grades	Higher concern because of unsaturation
Typical applications	Biologics, injectables, oral products	Oral, topical, selected parenteral products	Biologics, vaccines, injectables, emulsions
Market maturity	High	Mature but smaller	High
Supplier breadth	Broad	Moderate	Broad
Switching risk	High in approved products	High in approved products	High in approved products
Main commercial advantage	Established regulatory history	Palmitate-based surfactant profile	Broad formulation performance and biologic precedent

Polysorbate 40 may gain interest when a developer wants a saturated fatty-acid chain. That advantage does not automatically translate into adoption. A formulation change can require extensive comparability, stability, toxicology, and regulatory work, especially for parenteral products.

What is the market size and financial trajectory for polysorbate 40?

Public companies and excipient suppliers generally do not report revenue for polysorbate 40 as a separate line item. They aggregate it within pharmaceutical excipients, surfactants, specialty chemicals, or life-science ingredients. A defensible standalone global market figure therefore cannot be derived from audited public filings.

The financial trajectory is best assessed through market structure rather than a precise revenue estimate.

Financial driver	Directional impact
Growth in generic and branded oral formulations	Positive
Expansion of topical drug delivery	Positive
Biologic formulation demand	Positive for the category, but polysorbate 20 and 80 capture more volume
Pharmaceutical-grade conversion	Positive for margin
Raw-material costs	Variable
Ethylene oxide and oleochemical pricing	Direct cost exposure
Supplier qualification requirements	Supports pricing for validated grades
Product standardization	Limits pricing power
Customer switching costs	Supports incumbent suppliers
Industrial and cosmetic competition	Pressures price
Regulatory documentation burden	Increases cost to serve

A reasonable industry assessment is that polysorbate 40 should grow at a low- to mid-single-digit rate in volume over a normal cycle, with revenue growth depending on pharmaceutical-grade mix and input-cost pass-through. This is an analytical estimate, not a reported market statistic.

The most attractive financial segment is high-purity pharmaceutical material sold with:

• GMP manufacturing
• Full certificate-of-analysis packages
• Lot-to-lot fatty-acid and ethoxylate characterization
• Low peroxide and carbonyl specifications
• Microbial controls
• Trace-metal controls
• Change-control commitments
• Regulatory support files
• Regional inventory and supply continuity

Commodity grades face lower margins and greater substitution risk.

Which companies supply pharmaceutical-grade polysorbate 40?

The supplier landscape includes global excipient manufacturers, specialty chemical companies, and laboratory distributors. The commercial market is fragmented at the catalog level but more concentrated for fully qualified pharmaceutical-grade material.

Relevant supplier groups include:

• BASF, including Kolliphor-branded pharmaceutical excipients
• Croda Pharma and related specialty excipient operations
• Merck and Sigma-Aldrich distribution channels
• Avantor and VWR distribution channels
• Spectrum Chemical and other pharmaceutical raw-material distributors
• Regional producers in Asia serving pharmaceutical, food, and cosmetic markets

Catalog availability does not prove commercial GMP capacity. Pharmaceutical buyers normally distinguish between:

1. Research or laboratory grade
2. Food or cosmetic grade
3. Industrial grade
4. Pharmaceutical grade
5. Qualified grade for a specific formulation or manufacturing process

The highest-value supplier relationship is usually based on qualification history, audit results, supply continuity, and change-control performance rather than the lowest quoted price.

What manufacturing and quality barriers affect polysorbate 40 supply?

Polysorbate 40 is manufactured through esterification of sorbitan-related intermediates with palmitic acid, followed by ethoxylation. The commercial product is a distribution of related species rather than a single molecular entity.

Manufacturing variables include:

• Degree of ethoxylation
• Fatty-acid composition
• Free fatty acids
• Unreacted sorbitan derivatives
• Residual ethylene oxide
• Dioxane and other process-related impurities
• Water content
• Acid value
• Saponification value
• Hydroxyl value
• Peroxide value
• Carbonyl content
• Microbial burden

The product’s nonuniform molecular distribution creates analytical and comparability challenges. Two suppliers may both meet a compendial monograph while showing different performance in solubilization, interfacial behavior, oxidation, or protein compatibility.

For biologic and injectable applications, oxidative degradation is a central concern across the polysorbate family. Although polysorbate 40 is based on a saturated palmitate chain, the commercial material can contain minor unsaturated components and degradation-prone impurities. The risk profile depends on the manufacturing process, storage conditions, packaging, and test methods.

What patents protect polysorbate 40?

The basic polysorbate 40 composition is old and widely commercialized. It is unlikely to support meaningful new-product exclusivity by itself.

Potentially relevant intellectual-property categories include:

IP category	Commercial relevance
Composition patents	Low for basic polysorbate 40
Manufacturing-process patents	Moderate where purification or reaction control is distinctive
Low-peroxide or low-carbonyl grades	Moderate if supported by novel process claims
Pharmaceutical formulations	Potentially material
Protein stabilization methods	Potentially material
Drug-delivery systems	Potentially material
Packaging and storage systems	Limited but relevant
Analytical methods	Usually defensive or process-supporting
Supplier trade secrets	High practical relevance

A company could protect a formulation containing polysorbate 40 through claims directed to a particular active ingredient, concentration range, pH, buffer, antioxidant, container, or manufacturing step. That patent would protect the drug product or process, not the excipient as a standalone commodity.

When does polysorbate 40 lose exclusivity?

Polysorbate 40 does not have a single composition-patent expiration date comparable to a small-molecule active pharmaceutical ingredient. It is a mature excipient with broad historical commercialization.

The relevant exclusivity questions are instead:

• Whether a supplier has a live manufacturing-process patent
• Whether a formulation patent covers use of polysorbate 40
• Whether a customer has qualified a proprietary grade
• Whether a drug product patent covers the excipient combination
• Whether regulatory filings identify a specific supplier or specification

No general Paragraph IV pathway applies to polysorbate 40 itself. Paragraph IV certifications address patents listed for approved drug products in the FDA Orange Book. Excipients are not independently listed in the Orange Book as protected drug products (FDA, 2024).

What is the FDA regulatory and Orange Book status of polysorbate 40?

Polysorbate 40 is an inactive ingredient, not an active pharmaceutical ingredient. Its regulatory status depends on the dosage form, route of administration, concentration, product-specific toxicology, and manufacturing quality.

The FDA Inactive Ingredient Database is the main public reference for prior use in approved products. Developers should evaluate the database by:

• Exact excipient name
• Route of administration
• Dosage form
• Maximum potency or concentration
• Product precedent
• Whether the intended use is materially different from listed uses

The Orange Book does not provide a patent or exclusivity listing for polysorbate 40 as an excipient. Drug products containing it may have active patents, use codes, or regulatory exclusivities, but those rights attach to the finished product.

The European Pharmacopoeia and United States Pharmacopeia provide compendial frameworks for identity and quality where a relevant monograph applies. Compliance with a monograph does not eliminate the need for formulation-specific qualification or supplier controls (European Directorate for the Quality of Medicines & HealthCare, 2024; United States Pharmacopeial Convention, 2024).

Which companies are challenging polysorbate 40 suppliers?

There is no conventional generic challenge market for polysorbate 40. Competition occurs through supplier substitution and customer qualification.

Competitive threats include:

• Polysorbate 20
• Polysorbate 80
• Poloxamers
• Lecithin and phospholipid systems
• Sucrose esters
• PEG-based surfactants
• Cyclodextrins
• Protein-specific stabilizers
• Nonionic surfactants designed for biologic formulations

The strongest challenger is usually another qualified polysorbate supplier, not a legally challenging generic manufacturer. Customers may dual-source the excipient to reduce supply risk, but switching requires comparability data and often process validation.

What licensing deals and litigation affect polysorbate 40?

No major public licensing or patent-litigation pattern is associated with polysorbate 40 as a standalone excipient. Licensing activity is more likely to occur at the finished-drug level, in proprietary delivery platforms, or through supply and technology agreements that are not separately disclosed.

Potential disputes would more likely involve:

• Contract manufacturing
• Specification failures
• Batch contamination
• Change-control violations
• Supply interruption
• Product liability
• Finished-formulation patents
• Trade-secret claims involving purification or analytical methods

The absence of prominent public litigation does not mean that the supply chain is free of contractual or quality disputes. It means that polysorbate 40 is not generally litigated like a high-value branded active ingredient.

How strong is the polysorbate 40 patent estate?

The standalone patent estate is weak from an exclusivity perspective but can be commercially relevant at the process and application levels.

Patent-strength factor	Assessment
Basic molecule protection	Weak or effectively unavailable
Long-term composition exclusivity	Weak
Manufacturing know-how	Moderate
Purification and impurity control	Moderate
Finished-drug formulation claims	Potentially strong
Supplier switching barriers	Moderate to high after qualification
Orange Book leverage	None for the excipient alone
Litigation exposure	Concentrated in downstream products

The main economic moat is operational. It includes validated manufacturing, consistent raw materials, regulatory history, customer approvals, and dependable supply.

What generic launch risks exist for drugs containing polysorbate 40?

Polysorbate 40 normally does not block generic entry by itself. Generic-launch risk depends on the drug product’s listed patents, formulation claims, method-of-use claims, and regulatory requirements.

A generic manufacturer may need to address:

• Bioequivalence
• Pharmaceutical equivalence
• Excipient differences
• Comparative dissolution
• Stability
• Container compatibility
• Injectable safety
• Device or delivery-system compatibility
• Paragraph IV certifications for listed drug patents

A polysorbate 40 substitution can create regulatory risk if the reference product’s performance depends on a narrow surfactant specification. For conventional oral products, the barrier is usually lower than for complex injectables or biologics.

Biosimilar risk is indirect. Biosimilars may use polysorbate 40, but the excipient does not create biosimilar exclusivity. The relevant issues are analytical similarity, formulation comparability, immunogenicity, and manufacturing consistency.

How does geographic coverage affect polysorbate 40 commercialization?

Global commercialization depends on separate pharmacopeial, regulatory, and supply-chain requirements.

Key regions include:

• United States: FDA inactive-ingredient precedent, USP-NF, GMP expectations
• European Union: European Pharmacopoeia and excipient risk-management requirements
• Japan: Japanese Pharmacopoeia and local registration requirements
• China: Chinese Pharmacopoeia and domestic supplier qualification
• India: pharmaceutical manufacturing demand and export-oriented production
• Latin America: imported pharmaceutical-grade supply and regional registration requirements

A supplier with production in one region and distribution in another may face:

• Import controls
• Local representative requirements
• Dual compendial testing
• Longer lead times
• Customs exposure
• Regional inventory requirements
• Country-specific change notifications

Geographic diversification is commercially valuable because polysorbate 40 is inexpensive relative to many finished drugs, while a supply interruption can delay production disproportionately.

What is the commercial outlook for polysorbate 40?

The outlook is stable rather than high-growth.

Positive factors include continued pharmaceutical outsourcing, growth in liquid and topical formulations, expanding demand for high-purity excipients, and the need for validated alternative suppliers.

Constraints include limited biologic-platform penetration, substitution by polysorbate 20 and 80, price competition from Asian manufacturers, relatively low excipient content per dosage unit, and the absence of meaningful standalone patent exclusivity.

Revenue growth should favor suppliers that sell qualified pharmaceutical material rather than undifferentiated commodity product. Margin expansion will depend on:

• Higher share of GMP-grade sales
• Long-term supply contracts
• Customer qualification
• Specialty impurity specifications
• Regional warehousing
• Regulatory support
• Low failure and change-notification rates

Key Takeaways

• Polysorbate 40 is polyoxyethylene (20) sorbitan monopalmitate, CAS 9005-66-7.
• It is a mature nonionic surfactant used in oral, topical, emulsion, and selected parenteral formulations.
• Polysorbate 20 and polysorbate 80 have stronger positions in biologics and injectable products.
• Public companies do not generally report standalone polysorbate 40 revenue.
• The likely commercial trajectory is steady, low- to mid-single-digit volume growth rather than rapid expansion.
• Pharmaceutical-grade material commands a premium over food, cosmetic, and industrial grades.
• Basic composition patents provide little or no practical exclusivity.
• Manufacturing processes, impurity-control systems, qualified grades, and trade secrets create the main competitive barriers.
• Polysorbate 40 has no independent Orange Book or Paragraph IV framework.
• Downstream drug-product patents, not the excipient itself, determine most generic and biosimilar launch risk.
• Supply reliability and regulatory documentation are more important economic moats than patent ownership.

FAQs

Is polysorbate 40 the same as Tween 40?

Yes. Tween 40 is a commonly used commercial name for polysorbate 40, although supplier specifications and purity profiles can differ.

Is polysorbate 40 suitable for monoclonal antibody formulations?

It may be suitable in selected formulations, but polysorbate 20 and polysorbate 80 have broader industry precedent. Suitability must be established through protein-stability, oxidation, aggregation, particle, and container-compatibility studies.

Does polysorbate 40 require a Drug Master File?

A Drug Master File may support regulatory review, but the requirement depends on the supplier’s regulatory strategy, customer filing, jurisdiction, and level of confidential manufacturing information. A compendial monograph alone does not determine whether a DMF is needed.

Can a pharmaceutical company switch from polysorbate 80 to polysorbate 40?

Yes, but the switch normally requires formulation development, stability testing, impurity assessment, process evaluation, and regulatory review. The level of work is higher for injectable products and biologics.

Is polysorbate 40 exposed to ethylene oxide supply risk?

Yes. Ethylene oxide is a key process input, and supply interruptions, price changes, residual-control requirements, and regional safety restrictions can affect manufacturing economics and lead times.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia (11th ed.). Council of Europe.

2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

5. International Council for Harmonisation. (2023). ICH Q9(R1): Quality risk management. ICH.